Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NRIX

Nurix Therapeutics Inc

Nov 03 • 04:00PM ET

12.62

-0.32 -2.47 %

Healthcare • Biotechnology • USA • NASD

Peers: FATE CRSP BMRN EDIT NTLA TVRD BLUE KPTI RGNX PTGX

| Held by: IWM VTI ARKG XBI IWN VXF IBB SCHA VTWO IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.97	Insider Own	1.99%	Shs Outstand	101.37M	Perf Week	5.34%
Market Cap	1.28B	Forward P/E	-	EPS next Y	-3.66	Insider Trans	-1.71%	Shs Float	99.32M	Perf Month	34.54%
Enterprise Value	906.94M	PEG	-	EPS next Q	-1.00	Inst Own	87.65%	Short Float	13.96%	Perf Quarter	11.58%
Income	-244.78M	P/S	15.29	EPS this Y	-9.54%	Inst Trans	1.23%	Short Ratio	11.33	Perf Half Y	15.36%
Sales	83.69M	P/B	2.61	EPS next Y	-16.14%	ROA	-47.25%	Short Interest	13.87M	Perf YTD	-33.01%
Book/sh	4.84	P/C	2.98	EPS next 5Y	-5.97%	ROE	-65.35%	52W High	29.56 -57.31%	Perf Year	-47.57%
Cash/sh	4.23	P/FCF	-	EPS past 3/5Y	-1.82% -38.86%	ROIC	-57.60%	52W Low	8.18 54.28%	Perf 3Y	3.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	22.40% 11.88%	Gross Margin	77.86%	Volatility	8.04% 7.92%	Perf 5Y	-56.03%
Dividend TTM	-	EV/Sales	10.84	EPS Y/Y TTM	-1.91%	Oper. Margin	-319.32%	ATR (14)	0.80	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.35	Sales Y/Y TTM	48.32%	Profit Margin	-292.50%	RSI (14)	67.25	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	5.35	EPS Q/Q	-52.65%	SMA20	16.64%	Beta	1.91	Target Price	26.83
Payout	-	Debt/Eq	0.15	Sales Q/Q	-37.29%	SMA50	28.87%	Rel Volume	1.77	Prev Close	12.94
Employees	286	LT Debt/Eq	0.14	Earnings	Oct 09 AMC	SMA200	5.17%	Avg Volume	1.22M	Price	12.62
IPO	Jul 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-26.01% -50.80%	Trades		Volume	2,124,781	Change	-2.47%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Initiated	Mizuho	Outperform	$24
Mar-17-25	Initiated	Leerink Partners	Market Perform	$16
Dec-10-24	Initiated	BTIG Research	Buy	$35
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$35
Oct-24-24	Initiated	UBS	Buy	$35
Oct-11-24	Initiated	Jefferies	Buy	$41
Sep-06-24	Resumed	Robert W. Baird	Outperform	$26
Jul-31-24	Initiated	Truist	Buy	$36
Jun-26-23	Resumed	Oppenheimer	Outperform	$25
Mar-09-23	Initiated	Barclays	Overweight	$20
Feb-28-23	Initiated	Oppenheimer	Outperform	$25
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight	$11
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$25
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$28
Dec-29-21	Initiated	H.C. Wainwright	Buy	$62
Oct-14-21	Initiated	SVB Leerink	Outperform	$50
Jun-04-21	Resumed	Robert W. Baird	Outperform	$45 → $46
Apr-30-21	Resumed	Piper Sandler	Overweight	$60
Apr-30-21	Initiated	RBC Capital Mkts	Outperform	$42
Apr-14-21	Initiated	Berenberg	Buy

Show Previous Ratings

Nov-03-25 09:00AM	Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-30-25 07:00AM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +9.23%
Oct-27-25 07:00AM	Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock (GlobeNewswire) +8.03%
Oct-22-25 07:20AM	Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock (GlobeNewswire)
06:00AM	Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia (GlobeNewswire)
03:00AM	Loading…
Oct-18-25 03:00AM	Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress (GlobeNewswire)
Oct-17-25 09:00AM	Precision Oncology Approaches Drive $312B Market Transformation (PR Newswire)
Oct-09-25 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +8.82% -10.13%
04:01PM	Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Sep-25-25 09:29AM	Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks)
Sep-17-25 07:00AM	Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis (GlobeNewswire)
Sep-11-25 08:05AM	KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Aug-28-25 04:01PM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-15-25 10:10AM	Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright (TipRanks)
Jul-09-25 04:01PM	Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire) +7.94%
07:00AM	Loading…
Jul-07-25 07:00AM	European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia (GlobeNewswire)
07:00AM	European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenstrom Macroglobulinemia (GlobeNewswire)
Jul-03-25 10:00AM	Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
09:55AM	Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know (Zacks)
Jul-01-25 10:29AM	Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock? (Zacks)
Jun-17-25 05:15PM	Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Jun-13-25 04:01PM	Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-12-25 07:00AM	Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM) (GlobeNewswire) -5.30%
07:00AM	Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenstrom Macroglobulinemia (WM) (GlobeNewswire)
Jun-06-25 07:00AM	Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025) (GlobeNewswire)
Jun-03-25 09:09AM	Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last? (Zacks)
Jun-02-25 08:12AM	Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout (Benzinga) +14.21%
07:00AM	Sanofi Exercises License Extension Option to Nurix's STAT6 Program (GlobeNewswire)
May-28-25 07:00AM	Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-25 04:00PM	Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Loading…
May-15-25 07:00AM	Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-14-25 09:30AM	Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma (GlobeNewswire)
May-13-25 08:48AM	Why Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy Now (Insider Monkey)
Apr-28-25 04:00PM	Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs (GlobeNewswire)
Apr-25-25 01:00PM	Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets (GlobeNewswire)
Apr-17-25 05:07PM	Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential (Seeking Alpha)
07:00AM	Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions (GlobeNewswire)
Apr-11-25 04:01PM	Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.77%
Apr-08-25 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-03-25 09:08AM	NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program (Zacks) -7.64%
Apr-02-25 10:00AM	Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +8.69%
07:00AM	Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases (GlobeNewswire)
Mar-31-25 05:15PM	Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -11.87%
Mar-27-25 05:20PM	Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-25-25 04:30PM	Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting (GlobeNewswire) -5.70%
Mar-17-25 07:00AM	Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenstrom Macroglobulinemia (GlobeNewswire)
07:00AM	Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenstr m Macroglobulinemia (GlobeNewswire)
Mar-14-25 04:00PM	Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-13-25 04:00PM	Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors (GlobeNewswire) -9.28%
Mar-04-25 07:00AM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-25 04:01PM	Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-04-25 07:00AM	Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-28-25 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:00PM	Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jan-22-25 07:00AM	Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer (GlobeNewswire)
Jan-13-25 07:00AM	Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases (GlobeNewswire)
Jan-06-25 07:00AM	Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-24 07:00AM	Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia (GlobeNewswire)
Dec-11-24 12:05PM	Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers? (Insider Monkey)
Dec-09-24 06:00PM	Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting (GlobeNewswire) +6.78%
Dec-04-24 01:10PM	Why Is Nurix Therapeutics, Inc. (NRIX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-02-24 07:00AM	Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-25-24 07:00AM	Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-20-24 04:00PM	Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia (GlobeNewswire)
Nov-17-24 10:30AM	Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 (GlobeNewswire)
Nov-05-24 09:00AM	Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-24 07:00AM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-21-24 04:00PM	Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit (GlobeNewswire)
05:45AM	Nurix Therapeutics NX-5948 shows promise in Waldenstroms macroglobulinaemia trial (Clinical Trials Arena)
Oct-19-24 08:00AM	Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia (GlobeNewswire)
Oct-16-24 04:35PM	Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur (GlobeNewswire)
Oct-11-24 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +8.10% +6.47%
04:00PM	Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-09-24 07:00AM	Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology (GlobeNewswire)
Sep-30-24 07:00AM	Nurix Therapeutics Announces Presentations at Discovery on Target Conference (GlobeNewswire)
Sep-24-24 09:15AM	Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase (PR Newswire)
Sep-06-24 07:00AM	Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit (GlobeNewswire)
Sep-05-24 12:01AM	Nurix Therapeutics, Inc. (NRIX): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 07:00AM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-27-24 12:50AM	Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX) (GuruFocus.com)
Jul-25-24 09:55AM	How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27% (Zacks)
Jul-16-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice (Zacks)
Jul-11-24 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +8.84% +8.13%
04:00PM	Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-08-24 07:00AM	Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day (GlobeNewswire) +5.29%
Jun-20-24 07:02PM	Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX) (GuruFocus.com) +13.72%
05:26PM	Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike (PR Newswire)
Jun-19-24 05:05AM	Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains? (Zacks)
Jun-17-24 04:06PM	Nurix Therapeutics, With 345% Run, Posts A 'Clear Win' In Leukemia Treatment (Investor's Business Daily) +20.60%
08:45AM	Biotech Stock Nurix Therapeutics Jumps On Positive Leukemia Treatment Trial (Investor's Business Daily)
07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jun-16-24 05:30AM	Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) (GlobeNewswire)
Jun-10-24 07:00AM	Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024) (GlobeNewswire)
May-29-24 07:00AM	Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-24 07:00AM	Nurix Therapeutics Appoints Paula G. O'Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer (GlobeNewswire)
May-20-24 04:41PM	Nurix Therapeutics Names New Board Chair (MT Newswires)
04:00PM	Nurix Therapeutics Announces Board Chair Transition (GlobeNewswire)
10:21AM	Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last? (Zacks)

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rape, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
van Houte Hans	Chief Financial Officer	Nov 03 '25	Sale	12.56	6,284	78,931	37,592	Nov 03 07:14 PM
JOHANNES VAN HOUTE	Officer	Nov 03 '25	Proposed Sale	12.94	6,284	81,315		Nov 03 04:27 PM
van Houte Hans	Chief Financial Officer	Oct 30 '25	Option Exercise	0.00	11,494	0	47,006	Oct 30 06:06 PM
van Houte Hans	Chief Financial Officer	Oct 30 '25	Sale	12.80	3,130	40,054	43,876	Oct 30 06:06 PM
Ring Christine	Chief Legal Officer	Oct 30 '25	Option Exercise	0.00	10,532	0	54,541	Oct 30 06:02 PM
Ring Christine	Chief Legal Officer	Oct 30 '25	Sale	12.80	3,644	46,631	50,897	Oct 30 06:02 PM
Hansen Gwenn	Chief Scientific Officer	Oct 30 '25	Option Exercise	0.00	11,815	0	80,838	Oct 30 06:01 PM
Hansen Gwenn	Chief Scientific Officer	Oct 30 '25	Sale	12.80	4,087	52,300	76,751	Oct 30 06:01 PM
GREGORY JULIA P	Director	Sep 17 '25	Option Exercise	1.86	10,750	19,995	10,750	Sep 17 06:58 PM
van Houte Hans	Chief Financial Officer	Aug 01 '25	Sale	11.03	5,402	59,598	35,512	Aug 01 05:09 PM
JOHANNES VAN HOUTE	Officer	Aug 01 '25	Proposed Sale	11.26	5,402	60,827		Aug 01 04:28 PM
van Houte Hans	Chief Financial Officer	Jul 30 '25	Option Exercise	0.00	11,494	0	45,218	Jul 30 06:49 PM
van Houte Hans	Chief Financial Officer	Jul 30 '25	Sale	12.01	4,304	51,695	40,914	Jul 30 06:49 PM
Ring Christine	Chief Legal Officer	Jul 30 '25	Option Exercise	0.00	10,532	0	47,850	Jul 30 06:49 PM
Ring Christine	Chief Legal Officer	Jul 30 '25	Sale	12.01	3,841	46,134	44,009	Jul 30 06:49 PM
Hansen Gwenn	Chief Scientific Officer	Jul 30 '25	Option Exercise	0.00	11,815	0	73,331	Jul 30 06:48 PM
Hansen Gwenn	Chief Scientific Officer	Jul 30 '25	Sale	12.01	4,308	51,743	69,023	Jul 30 06:48 PM
van Houte Hans	Chief Financial Officer	May 02 '25	Sale	11.33	6,198	70,243	33,724	May 02 06:18 PM
JOHANNES VAN HOUTE	Officer	May 02 '25	Proposed Sale	11.16	6,198	69,170		May 02 04:22 PM
Hansen Gwenn	Chief Scientific Officer	Apr 30 '25	Option Exercise	0.00	8,956	0	64,893	Apr 30 07:35 PM
Hansen Gwenn	Chief Scientific Officer	Apr 30 '25	Sale	11.50	3,377	38,841	61,516	Apr 30 07:35 PM
Ring Christine	Chief Legal Officer	Apr 30 '25	Option Exercise	0.00	7,674	0	40,212	Apr 30 07:35 PM
Ring Christine	Chief Legal Officer	Apr 30 '25	Sale	11.50	2,894	33,286	37,318	Apr 30 07:35 PM
van Houte Hans	Chief Financial Officer	Apr 30 '25	Option Exercise	0.00	8,636	0	42,360	Apr 30 07:35 PM
van Houte Hans	Chief Financial Officer	Apr 30 '25	Sale	11.50	2,438	28,041	39,922	Apr 30 07:35 PM
van Houte Hans	Chief Financial Officer	Mar 03 '25	Sale	14.49	5,825	84,388	33,724	Mar 03 05:29 PM
JOHANNES VAN HOUTE	Officer	Mar 03 '25	Proposed Sale	15.45	5,825	89,996		Mar 03 04:17 PM
Ring Christine	Chief Legal Officer	Jan 31 '25	Option Exercise	1.86	5,760	10,714	38,298	Feb 03 08:03 PM
Ring Christine	Chief Legal Officer	Jan 31 '25	Sale	19.95	5,760	114,934	32,538	Feb 03 08:03 PM
CHRISTINE RING	Officer	Jan 31 '25	Proposed Sale	20.02	5,760	115,286		Jan 31 04:33 PM
Ring Christine	Chief Legal Officer	Jan 30 '25	Option Exercise	0.00	7,674	0	35,758	Jan 30 07:53 PM
Ring Christine	Chief Legal Officer	Jan 30 '25	Sale	19.85	3,220	63,929	32,538	Jan 30 07:53 PM
Hansen Gwenn	Chief Scientific Officer	Jan 30 '25	Option Exercise	0.00	8,957	0	59,627	Jan 30 07:48 PM
Hansen Gwenn	Chief Scientific Officer	Jan 30 '25	Sale	19.85	3,690	73,260	55,937	Jan 30 07:48 PM
van Houte Hans	Chief Financial Officer	Jan 30 '25	Option Exercise	0.00	8,636	0	42,360	Jan 30 07:43 PM
van Houte Hans	Chief Financial Officer	Jan 30 '25	Sale	19.85	2,811	55,809	39,549	Jan 30 07:43 PM
Ring Christine	Chief Legal Officer	Jan 02 '25	Option Exercise	1.86	5,760	10,714	33,844	Jan 02 05:28 PM
Ring Christine	Chief Legal Officer	Jan 02 '25	Sale	19.50	5,760	112,295	28,084	Jan 02 05:28 PM
CHRISTINE RING	Officer	Jan 02 '25	Proposed Sale	18.84	5,760	108,518		Jan 02 04:20 PM
Ring Christine	Chief Legal Officer	Dec 02 '24	Option Exercise	1.86	5,760	10,714	33,844	Dec 02 06:00 PM
Ring Christine	Chief Legal Officer	Dec 02 '24	Sale	21.73	5,760	125,155	28,084	Dec 02 06:00 PM
CHRISTINE RING	Officer	Dec 02 '24	Proposed Sale	22.11	5,760	127,354		Dec 02 04:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NRIX

Nurix Therapeutics Inc

Upgrade your FINVIZ experience